Showing results (451-460 of 760) with videos related to

Sort By:
Pageof 76
Journal of Immunotherapy (Hagerstown, Md. : 1997)|April 2, 2002
CD20-directed serotherapy in patients with multiple myeloma: biologic considerations and therapeutic applicationsSteven P Treon, Linda M Pilarski, Andrew R Belch, et al.
Blood Advances|December 7, 2020
A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myelomaNikhil C Munshi, Herve Avet-Loiseau, Kenneth C Anderson, et al.
Blood Cancer Journal|July 15, 2026
The role of RAD23A in DNA repair and proteasome-dependent protein degradation in multiple myelomaXueping Wan, Ting Du, Teng Fang, et al.
British Journal of Haematology|May 8, 2013
TRIM13 (RFP2) downregulation decreases tumour cell growth in multiple myeloma through inhibition of NF Kappa B pathway and proteasome activityMoshe E Gatt, Kohichi Takada, Mala Mani, et al.
Blood|November 18, 2021
IgM-MM is predominantly a pre-germinal center disorder and has a distinct genomic and transcriptomic signature from WMAbdul Hamid Bazarbachi, Hervé Avet-Loiseau, Raphael Szalat, et al.
Blood|May 28, 2009
Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myelomaPaul Richardson, Sundar Jagannath, Mohamad Hussein, et al.
Blood|August 5, 2009
Aurora kinase A is a target of Wnt/beta-catenin involved in multiple myeloma disease progressionJui Dutta-Simmons, Yunyu Zhang, Gullu Gorgun, et al.
British Journal of Haematology|November 7, 2008
In vivo anti-myeloma activity and modulation of gene expression profile induced by valproic acid, a histone deacetylase inhibitorPaola Neri, Pierosandro Tagliaferri, Maria Teresa Di Martino, et al.
British Journal of Haematology|May 30, 2012
Perifosine plus lenalidomide and dexamethasone in relapsed and relapsed/refractory multiple myeloma: a Phase I Multiple Myeloma Research Consortium studyAndrzej J Jakubowiak, Paul G Richardson, Todd Zimmerman, et al.
Blood|April 30, 2016
APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironmentYu-Tzu Tai, Chirag Acharya, Gang An, et al.
Pageof 76